Orthocell picks up US patent for Celgro

Orthocell (ASX:OCC) has secured a US patent covering the manufacture of its Celgro soft tissue reconstruction technology.

The patent covers the manufacture of collagen bio-scaffolds to aid in the surgical repair of soft tissue injuries, as well as the delivery of stem cells to surgical sites.

It comes less than two weeks after the company picked up a Chinese patent covering the same application. Orthocell also has patents in Singapore and New Zealand.

“This patent further strengthens our international IP position for our soft tissue reconstruction technology,” Orthocell Managing Director Paul Anderson said.

“[It] comes at a perfect time for the company as we move our products through international registration processes as well as commercial partnerships such as our recent BoneSupport agreement.”

Orthocell plans to file its first regulatory application for Celgro in the third quarter. The company is currently expanding production capacity to support future sales.

Celgro has applications in the repair of injuries involving tendons, cartilage, bone and tissue. The company is also exploring its potential application in surgical reconstructive applications for which there are no approved synthetic scaffolds, including hernia and vaginal wall soft tissue repair.

Orthocell (ASX:OCC) shares were trading unchanged at $0.40 as of around 1 pm on Monday.